Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide in Prader-Willi Syndrome
NCT01542242Phase 4Terminated
- Sponsor
- Vancouver General Hospital
- Start
- Feb 2012
- Primary completion
- Mar 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM) and Prader-Willi syndrome (PWS), sponsored by Vancouver General Hospital. Primary endpoint: Hemoglobin A1C at 12 months. Started Feb 2012; status: terminated.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT01542242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01542242.